Based on this evidence, the goal of this study was to understand whether high levels of cholesterol, through ERRα pathway activation, are able to determine, by themselves, an aggressive and resistant tumor phenotype, or whether another biosynthetic intermediate is required to observe these phenomena. The gene discussed is ESRRA; the disease is neoplasm.